Page 1142 - Williams Hematology ( PDFDrive )

1116 Part VIII: Monocytes and Macrophages Chapter 71: Inflammatory and Malignant Histiocytosis 1117

54. Donadieu J, Rolon MA, Pion I, et al: Incidence of growth hormone deficiency in pedi- 85. Weitzman S, Braier J, Donadieu J, et al: 2’-Chlorodeoxyadenosine (2-CdA) as salvage
atric-onset Langerhans cell histiocytosis: Efficacy and safety of growth hormone treat- therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of
ment. J Clin Endocrinol Metab 89:604–609, 2004. the Histiocyte Society. Pediatr Blood Cancer 53:1271–1276, 2009.
55. Geissmann F, Thomas C, Emile JF, et al: Digestive tract involvement in Langerhans 86. Bernard F, Thomas C, Bertrand Y, et al: Multi-centre pilot study of 2-chlorodeoxyade-
cell histiocytosis. The French Langerhans Cell Histiocytosis Study Group. J Pediatr nosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell
129:836–845, 1996. histiocytosis with haematological dysfunction. Eur J Cancer 41:2682–2689, 2005.
56. Hait E, Liang M, Degar B, Glickman J, Fox VL: Gastrointestinal tract involve- 87. Simko SJ, Tran HD, Jones J, et al: Clofarabine salvage therapy in refractory multifocal
ment in Langerhans cell histiocytosis: Case report and literature review. Pediatrics histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranu-
2006;118:e1593–e1599. loma and Rosai-Dorfman disease. Pediatr Blood Cancer 61:479–487, 2014.
57. Grois N, Prayer D, Prosch H, et al: Course and clinical impact of magnetic resonance 88. Abraham A, Alsultan A, Jeng M, Rodriguez-Galindo C, Campbell PK: Clofarabine sal-
imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis. vage therapy for refractory high-risk langerhans cell histiocytosis. Pediatr Blood Cancer
Pediatr Blood Cancer 43:59–65, 2004. 2013;60:E19–E22.
58. Fahrner B, Prosch H, Minkov M, et al: Long-term outcome of hypothalamic pituitary 89. Rodriguez-Galindo C, Jeng M, Khuu P, McCarville MB, Jeha S: Clofarabine in refrac-
tumors in Langerhans cell histiocytosis. Pediatr Blood Cancer 58:606–610, 2012. tory Langerhans cell histiocytosis. Pediatr Blood Cancer 51:703–706, 2008.
59. Prayer D, Grois N, Prosch H, Gadner H, Barkovich AJ: MR imaging presentation of 90. Pratilas CA, Xing F, Solit DB: Targeting oncogenic BRAF in human cancer. Curr Top
intracranial disease associated with Langerhans cell histiocytosis. AJNR Am J Neurora- Microbiol Immunol 355:83–98, 2012.
diol 25:880–891, 2004. 91. Haroche J, Cohen-Aubart F, Emile JF, et al: Dramatic efficacy of vemurafenib in both
60. Grois N, Prayer D, Prosch H, Lassmann H: Neuropathology of CNS disease in Langer- multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocyto-
hans cell histiocytosis. Brain 128:829–838, 2005. sis harboring the BRAF V600E mutation. Blood 121:1495–1500, 2013.
61. Grois N, Fahrner B, Arceci RJ, et al: Central nervous system disease in Langerhans cell 92. Cooper N, Rao K, Goulden N, et al: The use of reduced-intensity stem cell transplanta-
histiocytosis. J Pediatrics 2010;156:873–81, 881. tion in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone
62. Wnorowski M, Prosch H, Prayer D, et al: Pattern and course of neurodegeneration in Marrow Transplant 2008;42 Suppl 2:S47–S50.
Langerhans cell histiocytosis. J Pediatrics 153:127–132, 2008. 93. Haupt R, Nanduri V, Calevo MG, et al: Permanent consequences in Langerhans cell his-
63. Calming U, Henter JI: Elevated erythrocyte sedimentation rate and thrombocytosis tiocytosis patients: A pilot study from the Histiocyte Society-Late Effects Study Group.
as possible indicators of active disease in Langerhans’ cell histiocytosis. Acta Paediatr Pediatr Blood Cancer 42:438–444, 2004.
87:1085–1087, 1998. 94. Willis B, Ablin A, Weinberg V, et al: Disease course and late sequelae of Langerhans’ cell
64. Phillips M, Allen C, Gerson P, McClain K: Comparison of FDG-PET scans to con- histiocytosis: 25-year experience at the University of California, San Francisco. J Clin
ventional radiography and bone scans in management of Langerhans cell histiocytosis. Oncol 14:2073–2082, 1996.
Pediatr Blood Cancer 52:97–101, 2009. 95. Nanduri VR, Lillywhite L, Chapman C, et al: Cognitive outcome of long-term survivors
65. Almanaseer IY, Kosova L, Pellettiere EV: Composite lymphoma with immunoblas- of multisystem langerhans cell histiocytosis: A single-institution, cross-sectional study.
tic features and Langerhans’ cell granulomatosis (histiocytosis X). Am J Clin J Pathol J Clin Oncol 21:2961–2967, 2003.
85:111–114, 1986. 96. Mittheisz E, Seidl R, Prayer D, et al: Central nervous system-related permanent conse-
66. Burns BF, Colby TV, Dorfman RF: Langerhans’ cell granulomatosis (histiocytosis X) quences in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 48:50–56,
associated with malignant lymphomas. Am J Surg. J Pathol 7:529–533, 1983. 2007.
67. Egeler RM, Neglia JP, Arico M, et al: The relation of Langerhans cell histiocytosis to 97. Egeler RM, Neglia JP, Puccetti DM, Brennan CA, Nesbit ME: Association of Langerhans
acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study cell histiocytosis with malignant neoplasms. Cancer 71:865–873, 1993.
Group of the Histiocyte Society. Hematol Oncol Clin North Am 12:369–378, 1998. 98. Feldman AL, Berthold F, Arceci RJ, et al: Clonal relationship between precursor T-lym-
68. Bramwell NH, Burns BF: Histiocytosis X of the thymus in association with myasthenia phoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol
gravis. Am J Clin J Pathol 86:224–227, 1986. 6:435–437, 2005.
69. Steen AE, Steen KH, Bauer R, Bieber T: Successful treatment of cutaneous Langerhans 99. Rodig SJ, Payne EG, Degar BA, et al: Aggressive Langerhans cell histiocytosis following
cell histiocytosis with low-dose methotrexate. Br J Dermatol 145:137–140, 2001. T-ALL: Clonally related neoplasms with persistent expression of constitutively active
70. McClain KL, Kozinetz C: A phase II trial using thalidomide for Langerhans cell histio- NOTCH1. Am J Hematol 83:116–121, 2008.
cytosis. Pediatr Blood Cancer 48(1):44–49, 2007. 100. Yohe SL, Chenault CB, Torlakovic EE, Asplund SL, McKenna RW: Langerhans cell histi-
71. Hoeger PH, Nanduri VR, Harper JI, Atherton DA, Pritchard J: Long term follow up of ocytosis in acute leukemias of ambiguous or myeloid lineage in adult patients: Support
topical mustine treatment for cutaneous langerhans cell histiocytosis. Arch Dis Child for a possible clonal relationship. Mod Pathol 27:651–656, 2014.
82:483–487, 2000. 101. Baumgartner I, von HA, Baumert B, Luetolf U, Follath F: Langerhans’-cell histiocytosis
72. Kwon OS, Cho KH, Song KY: Primary cutaneous Langerhans cell histiocytosis treated in adults. Med Pediatr Oncol 28:9–14, 1997.
with photochemotherapy. J Dermatology 24:54–56, 1997. 102. Gotz G, Fichter J: Langerhans’-cell histiocytosis in 58 adults. Eur J Med Res 9:510–514,
73. Nauert C, Zornoza J, Ayala A, Harle TS: Eosinophilic granuloma of bone: Diagnosis 2004.
and management. Skeletal Radiol 10:227–235, 1983. 103. Tazi A, Moreau J, Bergeron A, et al: Evidence that Langerhans cells in adult pulmonary
74. Nesbit ME, Kieffer S, D’Angio GJ: Reconstitution of vertebral height in histiocytosis X: Langerhans cell histiocytosis are mature dendritic cells: Importance of the cytokine
A long-term follow-up. J Bone Joint Surg Am 51:1360–1368, 1969. microenvironment. J Immunol 163:3511–3515, 1999.
75. Womer RB, Raney RB Jr, D’Angio GJ: Healing rates of treated and untreated bone 104. Yousem SA, Colby TV, Chen YY, Chen WG, Weiss LM: Pulmonary Langerhans’ cell
lesions in histiocytosis X. Pediatrics 76:286–288, 1985. histiocytosis: Molecular analysis of clonality. Am J Surg Pathol 25:630–636, 2001.
76. Mammano S, Candiotto S, Balsano M: Cast and brace treatment of eosinophilic granu- 105. Yousem SA, Dacic S, Nikiforov YE, Nikiforova M: Pulmonary Langerhans cell histi-
loma of the spine: Long-term follow-up. J Pediatr Orthop 17:821–827, 1997. ocytosis: Profiling of multifocal tumors using next-generation sequencing identifies
77. Raney RB Jr, D’Angio GJ: Langerhans’ cell histiocytosis (histiocytosis X): Experience concordant occurrence of BRAF V600E mutations. Chest 143:1679–1684, 2013.
at the Children’s Hospital of Philadelphia, 1970–1984. Med Pediatr Oncol 17:20–28, 106. Roden AC, Hu X, Kip S, et al: BRAF V600E expression in Langerhans cell histiocytosis:
1989. Clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary
78. Morimoto A, Ikushima S, Kinugawa N, et al: Improved outcome in the treatment of cases. Am J Surg Pathol 38:548–551, 2014.
pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans 107. Kaltsas GA, Powles TB, Evanson J, et al: Hypothalamo-pituitary abnormalities in adult
Cell Histiocytosis Study Group-96 protocol study. Cancer 107:613–619, 2006. patients with Langerhans cell histiocytosis: Clinical, endocrinological, and radiological
79. Dhall G, Finlay JL, Dunkel IJ, et al: Analysis of outcome for patients with mass lesions of features and response to treatment. J Clin Endocrinol Metab 85:1370–1376, 2000.
the central nervous system due to Langerhans cell histiocytosis treated with 2-chloro- 108. Edelbroek JR, Vermeer MH, Jansen PM, et al: Langerhans cell histiocytosis first pre-
deoxyadenosine. Pediatr Blood Cancer 50:72–79, 2008 senting in the skin in adults: Frequent association with a second haematological malig-
80. Idbaih A, Donadieu J, Barthez MA, et al: Retinoic acid therapy in “degenerative-like” nancy. Br J Dermatol Dermatology 167:1287–1294, 2012.
neuro-langerhans cell histiocytosis: A prospective pilot study. Pediatr Blood Cancer 109. Slater JM, Swarm OJ: Eosinophilic granuloma of bone. Med Pediatr Oncol 8:151–164,
43:55–58, 2004. 1980.
81. Imashuku S, Okazaki N, Nakayama M, et al: Treatment of neurodegenerative CNS dis- 110. Schonfeld N, Frank W, Wenig S, et al: Clinical and radiologic features, lung function
ease in Langerhans cell histiocytosis with a combination of intravenous immunoglobu- and therapeutic results in pulmonary histiocytosis X. Respiration 60:38–44, 1993.
lin and chemotherapy. Pediatr Blood Cancer 50:308–311, 2008. 111. Travis WD, Borok Z, Roum JH, et al: Pulmonary Langerhans cell granulomatosis
82. Allen CE, Flores R, Rauch R, et al: Neurodegenerative central nervous system Langer- (histiocytosis X). A clinicopathologic study of 48 cases. Am J Surg Pathol 17:971–986,
hans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine 1993.
arabinoside. Pediatr Blood Cancer 54:416–423, 2010. 112. Crausman RS, Jennings CA, Tuder RM, et al: Pulmonary histiocytosis X: Pulmonary
83. Egeler RM, de KJ, Voute PA: Cytosine-arabinoside, vincristine, and prednisolone in function and exercise pathophysiology. Am J Respir Crit Care Med 153:426–435, 1996.
the treatment of children with disseminated Langerhans cell histiocytosis with organ 113. Delobbe A, Durieu J, Duhamel A, Wallaert B: Determinants of survival in pulmonary
dysfunction: Experience at a single institution. Med Pediatr Oncol 21:265–270, 1993. Langerhans’ cell granulomatosis (histiocytosis X). Groupe d’Etude en Pathologie Inter-
84. Simko SJ, Tran HD, Jones J, et al: Clofarabine salvage therapy in refractory multifocal stitielle de la Societe de Pathologie Thoracique du Nord. Eur Respir J 9:2002–2006, 1996.
histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranu- 114. Tazi A, Marc K, Dominique S, et al: Serial computed tomography and lung function
loma and Rosai-Dorfman disease. Pediatr Blood Cancer 61:479–487, 2014. testing in pulmonary Langerhans’ cell histiocytosis. Eur Respir J 40:905–912, 2012.

Kaushansky_chapter 71_p1101-1120.indd 1117 9/17/15 3:51 PM